Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
June 04, 2024 16:10 ET
|
Abivax
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the...
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
May 08, 2024 02:30 ET
|
Abivax
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 PARIS, France, May 8, 2024, 8:30 a.m. CEST –...
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
May 07, 2024 16:00 ET
|
Abivax
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 Availability of the preparatory documents PARIS, France, May 7, 2024, 10:00PM CEST – Abivax SA (Euronext Paris & Nasdaq:...
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
April 05, 2024 16:00 ET
|
Abivax
Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France, April 5, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or...
Abivax reports 2023 financial results and operational update
April 02, 2024 02:30 ET
|
Abivax
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and...
Abivax appoints Ana Sharma as Vice President, Global Head of Quality
February 07, 2024 02:30 ET
|
Abivax
Abivax appoints Ana Sharma as Vice President, Global Head of Quality PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a...
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
February 02, 2024 02:30 ET
|
Abivax
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease Obefazimod Crohn’s Disease (CD) IND filed with the FDA in December...
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
January 24, 2024 02:30 ET
|
Abivax
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 PARIS,...
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
January 22, 2024 02:30 ET
|
Abivax
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months Induction data read-out expected Q1 2025 from the pivotal Phase 3 ABTECT program evaluating obefazimod in...
Abivax 2024 Financial Communication Calendar
January 04, 2024 02:30 ET
|
Abivax
Abivax 2024 Financial Communication Calendar PARIS, France, January 4, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage...